Genetic Susceptibility

Blog Archives

Clinical evidence and implementation challenges for pharmacogenomic testing

Posted on September 18, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Personomics, Pharmacogenetics, Thasso Post, Theragenomic Medicine No Comments ↓

September 18, 2019 – This post is an edited version of parts of a paper that appeared in the Journal of Personalised Medicine (JPM) a week ago und which addresses one of the important topics in connection with the themes of personalised medicine,

…

Tags: All of Us Project, Canadian Association of Genetic Counsellors, Clinical Pharmacogenetics Implementation Consortium (CPIC), Direct To Consumer Genetic Testing (DTCGT), Dutch Pharmacogenetics Working Group (DPWG), Genetic Testing, Next Generation Sequencing (NGS), Pharmacogenomics, PharmGKB, PREDICT Program, Right Dose, Right Drug, Right Time Protocol (RIGHT Protocol), Thasso Post, Theragenomic Medicine, Ubiquitous Pharmacogenomics Project (UPGX), US National Society of Genetic Counselors

ZRANB3 in African Populations: New Type 2 Diabetes risk locus identified

Posted on August 3, 2019 by by

thassodotcom Posted in Ethnicity, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

August 03, 2019 – Africa is considered the original cradle of all humanity, to which all humans can trace their genetic origin. This may be very interesting in the context of diseases that are due to genetic predispositions both in todays African populations and in all the populations descendant of African origin worldwide.

…

Tags: 1000 Genomes Project (1KGP), African Population, Genome Aggregation Database (GnomAD), Risk Locus, T2D, Thasso Post, Theragenomic Medicine, Type 2 Diabetes, ZRANB3 Gene

Genetic aspects of globesity: Glocalized or not?

Posted on June 25, 2019 by by

thassodotcom Posted in Allelic Variant, Gene Expression, Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

June 25, 2019 – The global obesity epidemic is so far-reaching it now has an overarching name: globesity (obviously derived from global obesity). Very interesting questions arise in this context such as are there glocalized (global and or local) factors involved in this epidemic.

…

Tags: Allelic Variant, Congenital Leptin Deficiency, Fat Controller, Globesity, Glocalization, LEP Gene, Leptin, Metreleptin [Myalept], Recessive Genetic Disorder, Thasso Post, Theragenomic Medicine

Status of genetics behind male infertility

Posted on June 20, 2019 by by

thassodotcom Posted in Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

June 20, 2019 – Male infertility is a serious treat in very many relations. While a priori, male infertility does not affect the physical health of the afflicted, it may very much affect the psychological health of the individual, and that of couples too.

In recent years,

…

Tags: Acrosome Biogenesis, CFAP43 Gene, CFAP44 Gene, DNAH1 Gene, DPY19L2 Gene, Endocrine Disruptor, Male Infertility, Multiple Morphological Anomalies of the Flagellum (MMAF Syndrome), RBMXL2 Gene, SPINK2 Gene, Thasso Post, Theragenomics Medicine

Genomics lab illegally markets genetic tests that claim to predict patient responses to drugs

Posted on April 7, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Pharmacogenetics, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,

…

Tags: American Food & Drug Administration (FDA), Direct To Consumer Genetic Testing (DTCGT), Direct To Consumer Theragenomic Testing (DTCTT), Inova Genomics Laboratory, MediMap ADHD, MediMap BabyToday, MediMap Heart, MediMap Mind, MediMap Plus

Your genes and your opioids: Pain relief or addiction? Or both?

Posted on March 14, 2019 by by

thassodotcom Posted in Genetic Background, Genetic Predisposition, Genetic Susceptibility, Thasso Post, Theragenomic Medicine No Comments ↓

March 14, 2019 – Genetic predisposition may help to explain opioid based pain relief, addiction, or the combination of both. In a perfect world, and in battling the rampant opioid crises in the US and other parts of the world, doctors would be able to identify those patients who are prone to opioid addiction and prescribe them non-opioid painkillers that wouldn’t lead to dependence.

…

Tags: A118G OPRM1 Allelic Variant, C17T OPRM1 Allelic Variant, C921T OPRD1 Allelic Variant, Dopamine D2 Receptor, Dopamine D4 Receptor, G80T OPRD1 Allelic Variant, Opioid, Opioid Epidemic, Opioid Receptor δ 1 (OPRD1), OPRM1 Gene, Thasso Post, Theragenomic Medicine

Is there an increased ALS risk in professional soccer playing?

Posted on March 14, 2019 by by

thassodotcom Posted in Genetic Predisposition, Genetic Susceptibility, Thasso Post, Theragenomic Medicine No Comments ↓

March 13, 2019 – Playing professional soccer; that is the ultimate dream of boys (and more and more girls too) all over the world, except, possibly, for boys in the US, where American Football and/or Baseball may be more prominently in the heads and dreams of boys.

…

Tags: Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD, Lou Gehrig's Disease, Motor Neurone Disease (MND), Professional Sport, Soccer, Thasso Post, Theragenomic Medicine

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk

Posted on December 20, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

…

Tags: Britisch Medical Journal (BMJ), Cholangiocarcinoma, Diabetes, Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, DPP-4 Inhibitor Class of Drugs, DPP4 Gene, GLP-1 Receptor Agonist, GLP1R Gene, Glucagon-Like Peptide-1 (GLP-1) Receptor, Glyxambi (Empagliflozin / Linagliptin), Janumet (Sitagliptin / Metformin), Januvia (Sitagliptin), Jentadueto (Linagliptin / Metformin), Kazano (Alogliptin / Metformin), Kombiglyze XR (Saxagliptin / Metformin), Nesina (Alogliptin), Onglyza (Saxagliptin), Oseni (Alogliptin / Pioglitazone), Qtern (Dapagliflozin / Saxagliptin), Thasso Post, Theragenomic Medicine, Tradjenta (Linagliptin)

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs

Posted on August 12, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Allelic Variant, Genetic Susceptibility, In The Press, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous pemphigoid,

…

Tags: Alogliptin (Nesina), Bullous Pemphigoid, Dipeptidyl Peptidase-4 (DPP-4), DPP-4 Inhibitor, HLA-DQB1*03:01 Allele, Japanese Adverse Drug Event Report Database (JADER), Linagliptin (Tradjenta), Saxagliptin [Onglyza], Sitagliptin [Januvia], Teneligliptin (Tenelia), Thasso Post, Theragenomic Medicine, Type 2 Diabetes, Vildagliptin (Galvus)

Breast cancer: Multigene sequencing replaces BRCA tests

Posted on May 15, 2018 by by

thassodotcom Posted in Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, Personalized Medicine, Targeted Therapy, Thasso Post No Comments ↓

May 15, 2018 –An increasing number of women who are diagnosed with breast cancer are opting for multigene sequencing instead of the more limited testing for only BRCA1/ BRCA2 mutations, according to a new report.

The findings come from the ICanCAre study,

…